Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases

First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerabilityKIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF)KIT2014’s unique mode of action improves respiratory symptoms by promoting bronchodilation and reducing lung inflammation TURIN, Italy, June 19, 2026 (GLOBE NEWSWIRE) -- Kither Biotech Pty Ltd and Kither Biotech